Navigation Links
Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data

  • Nine out of 10 non-diabetic patients treated with Exforge achieved recommended blood pressure goals[1]
  • Additional average decrease of 20 mmHg in systolic blood pressure observed in patients taking Exforge over reductions seen with previous monotherapy[1]
  • Nearly 70% of those with high blood pressure not at treatment target levels[2] and most require two or more medications to achieve goal[2]
BASEL, Switzerland, May 21, 2007 - Exforge®, a single-tablet combination of two of the world's most commonly prescribed high blood pressure medicines[3],[4], has been shown in new clinical data to have helped nine out of 10 non-diabetic patients to reach their treatment goals after having previously failed to do so with single medicines[1].
The results showed patients taking Exforge experienced on average an additional 20 mmHg drop in systolic blood pressure compared to reductions seen with their previous medication[1]. The data from this trial involving 894 patients were presented today at the Annual Scientific Meeting of the American Society of Hypertension (ASH) in Chicago.
The efficacy of Exforge, which combines the angiotensin receptor blocker (ARB) valsartan (Diovan®) and the calcium channel blocker (CCB) amlodipine in one tablet, was again demonstrated in this trial, even in patients considered to be more difficult to treat such as the elderly or those with type 2 diabetes[1]. Exforge was well-tolerated at the doses used in this trial[1].
The study - designed to assess the use of Exforge in a real-life treatment environment - showed that patients who had failed to reach the recommended blood pressure goal of 140/90 mmHg (systolic/diastolic pressure) on a range of si
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
2. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2
(Date:7/25/2014)... Stwd.co.uk, one of the leading dress manufacturers ... cheap evening dress for women. In addition, the ... for these items. They are available at discounted rates, ... August 30. , “We are pleased to announce our ... have a large number of stylish special occasion gowns ...
(Date:7/25/2014)... July 25, 2014 Healthpointe is ... clinic is offering Occupational Medicine services to ... happily accepting referrals and workers’ compensation cases. ... Mirada clinic include wound care treatment management, return-to-work ... assessments, pre-employment screening & physicals, and illness and ...
(Date:7/25/2014)... MEDICC announced diplomas went to 1,382 new ... University of Havana’s graduation ceremonies that also included graduates ... the 879 international graduates from 28 countries, 20 were ... Professors and hundreds of parents packed the Cuban labor ... Vice President Ramón Machado Ventura and Minister of Health ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 CMS recently ... health plans for providing inadequate access to prescription drugs. ... to the health and safety of beneficiaries in areas ... coverage determinations, and CMS is taking quick and firm ... Atlantic Information Services webinar, “Avoiding Costly Part D ...
(Date:7/25/2014)... 2014 According to the ... by Vkool.com, this is a comprehensive guide ... some common types of hemorrhoids including:, ... ,     Young children with hemorrhoids , ...     Very large hemorrhoids and chronic hemorrhoids ...
Breaking Medicine News(10 mins):Health News:Famous Supplier Stwd.co.uk Announces Its New Selection of Evening Dresses for Women 2Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3
... Parents on How to Help Children Cope, WESTPORT, ... that responds to disasters and works to improve the,lives ... of crisis experts,to assist children and families affected by ... will be posted to San Diego, will provide assistance ...
... People with Diabetes Affected ... by California Wildfires, ALEXANDRIA, Va., ... for people with diabetes who,are affected by the California wildfires. ... supplies to manage their health. 1) Medication and Supplies -- ...
... of children with attention deficit hyperactivity disorder (ADHD) at ... was missing: the fathers., Fabiano, an assistant professor in the ... a graduate assistant at the UB Center for Children ... has helped more than 2,500 children with behavioral, emotional ...
... Fisher,Scientific Inc. (NYSE: TMO ), the world ... ground on a new $17 million (USD) facility ... services in that,country. The facility will focus on ... pharmaceutical samples to,patients participating in clinical trials across ...
... Md., Oct. 23 Martek Biosciences,Corporation (Nasdaq: ... of a,district court in Dusseldorf, Germany, has orally ... company,s patent infringement suit against (i) Lonza,Ltd., (ii) ... Food Ingredients GmbH. In a separate suit against ...
... BOTHELL, Wash., Oct. 23 Cardiac Science,Corporation (Nasdaq: ... cardiac monitoring,and defibrillation products, announced today that it ... Tuesday, October 30, 2007 after the,market close. The ... and,investors for 4:30 p.m. Eastern Time to discuss ...
Cached Medicine News:Health News:Save the Children to Help Youngsters Impacted by California Wildfires 2Health News:Save the Children to Help Youngsters Impacted by California Wildfires 3Health News:Save the Children to Help Youngsters Impacted by California Wildfires 4Health News:Save the Children to Help Youngsters Impacted by California Wildfires 5Health News:Emergency Preparedness for People With Diabetes 2Health News:Getting fathers involved in children's ADHD treatment programs 2Health News:Getting fathers involved in children's ADHD treatment programs 3Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 2Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 3Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4Health News:Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements 2Health News:Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements 3Health News:Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: